Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
VANCOUVER, British Columbia, April 02, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, is pleased to announce that three validation batches of its Natural Psilocybin Extract have undergone full release testing and have been issued the Certificate of Analysis (COA) by a third-party, confirming compliance with Good Manufacturing Practice (GMP) specifications. Additionally, the Company has successfully completed the in-house encapsulation of psilocybin drug candidates in 5mg and 10mg dosage formats.
Related news for (OPTHF)
- Optimi Health Completes Largest-to-Date MDMA Export to Australia for PTSD Therapy
- Optimi Health Obtains U.S. FDA Drug Establishment Registration
- Optimi Health Provides Corporate Update
- Optimi Health Completes Largest MDMA Capsule Batch to Date, Expands Stability Program
- Optimi Health Announces Closing of Non-Brokered Private Placement and Debt Settlement